ArticlePloS one2025
Prevalence and factors influencing drug-resistant tuberculosis in four regions of Ghana.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe alarming rate of drug-resistant tuberculosis (DR-TB) globally is a threat to treatment success among positive tuberculosis (TB) cases. Studies aimed at determining the prevalence, trend of DR-TB and socio-demographic and clinical risk factors contributing to DR-TB in the four regions of Ghana are currently unknown. This study sought to determine the prevalence and trend of DR-TB, identify socio-demographic and clinical risk factors that influence DR-TB, and analyse the relationship between underweight and adverse drug reactions and treatment outcomes among DR-TB patients in four regions of Ghana.
methodIt was a retrospective review conducted over 5 years, from January 2018 to the end of December 2022. The data were retrieved from the DR-TB registers and folders at the Directly Observed Treatment (DOT) centres in the four regions. Analysis of the data was conducted using STATA version 17.
resultsThe prevalence of DR-TB in Ashanti was 10.1%, Eastern 5.3%, 27.8% in Central, and 2.7% in the Upper West region for the year 2022. The overall prevalence rate of DR-TB for the period 2018-2022 was 13.8%. The socio-demographic and clinical risk factors that influence DR-TB in the four regions are: age, marital status (aOR 3.58, P-value< 0.00, 95% CI 2.86-4.48), Senior High School (SHS) level of education (aOR 2.09, P-value = 0.01, 95% CI 1.21-3.63), alcohol intake (aOR 0.49, P-value <0.00, 95% CI 0.38-0.63), previously treated (aOR 22.03, P-value<0.00, CI 16.58-29.26), major adverse drug reaction (aOR 125.50, P-value<0.00, 95% CI 58.05-271.34), and minor adverse drug reaction (aOR 23.59, P-value<0.00, 95% CI 18.32-30.39); treatment outcome, cure (aOR 0.52, P-value<0.00, 95% CI 0.41-0.66), completed (aOR 9.67, P-value<0.00, 95% CI 6.56-14.28), relapsed (aOR 2.62, P-value = 0.01, 95% CI 1.33-5.18), Lost-to-Follow-up (LTFU) (aOR 0.45, P-value<0.00, 95% CI 0.29-0.70), and failure (aOR 35.24, P-value<0.00, 95% CI 7.76-159.99). Also, there was an association between underweight and adverse drug reaction (RRR 5.74, P-value<0.00, 95% CI 4.86-6.79) and treatment outcome (RRR 0.79, P-value<0.00, 95% CI 0.74-0.86).
conclusionThe study shows that the prevalence of DR-TB in Ghana is low, probably not because the cases have reduced but due to inadequate GeneXpert machines to detect the cases. Age, marital status, education, alcohol intake, previously treated TB cases, adverse drug reactions, underweight, and treatment outcome are factors influencing the development of DR-TB. Therefore, interventions aimed at improving the nutritional status of DR-TB cases and minimising adverse drug reactions will improve treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.